Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with its Q3 2024 financials, announced plans to lay off staff amid a delay in its ...
As mental health treatments evolve, COMPASS Pathways leads with psilocybin-based therapies targeting depression—does this position it for major gains ahead? For investors in the United States and ...
Compass Pathways plc (CMPS) has faced significant risks since my last 'Buy' rating in January 2026. CMPS shares had declined approximately 10% over the intervening months, but then registered huge ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CMPS stock reflects investor focus on Compass Pathways' late-stage psychedelic therapy programs and regulatory progress in mental health treatment. CMPS, GB00BKLLQZ68, Illustration mit AI erstellt.
Compass Pathways struck an optimistic tone on its latest earnings call, highlighting strong Phase III data, clear regulatory alignment, and growing commercial preparations for its COMP360 psychedelic ...
Hitting the primary endpoint on Compass Pathways plc’s Comp005 study of synthetic psilocybin, which the company billed as the first classic psychedelic to report phase III efficacy data, produced only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results